# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

### FORM 8-K

#### **CURRENT REPORT**

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

<u>January 4, 2022</u> (Date of earliest event reported)

### LABORATORY CORPORATION OF AMERICA HOLDINGS

	(Exact	Name of Registrant as Specified in its Char	ter)
Delaware		1-11353	13-3757370
(State or other jurisdiction of Incorporation)		(Commission File Number)	(I.R.S. Employer Identification No.)
	358 South Main Street		
Burlington, North Car		arolina	27215
	(Address of principal executive offices)		(Zip Code)
	(Registrant's t	telephone number including area code) 336-	-229-1127
Check the approfollowing provisi		g is intended to simultaneously satisfy the	e filing obligation of the registrant under any of the
<ul><li>□ Soliciting m</li><li>□ Pre-comme</li></ul>		· · · · · · · · · · · · · · · · · · ·	
Securities registe	red pursuant to Section 12(b) of the Exch	ange Act.	
<b>Title of Each Cla</b> Common Stock, S		of exchange on which registered ork Stock Exchange	
-	a mark whether the registrant is an emergi 12b-2 of the Securities Exchange Act of 1 Emerging growth company		of the Securities Act of 1933 (§230.405 of this
	owth company, indicate by check mark if	f the registrant has elected not to use the ext nt to Section 13(a) of the Exchange Act. $\Box$	ended transition period for complying with any new
Item 7.01	Regulation FD Disclosure		
		npany, today announced that members of care Conference on Tuesday, Jan. 11 at 4:30	the executive management team will participate in a p.m. (ET).
A live webcast of	f the fireside chat will be available via the	Company website at www.Labcorp.com ar	nd archived for replay.
Item 9.01	Financial Statements and Exhibits	s <b>.</b>	
Exhibit Exhibit 99.1	Exhibit Name Press Release dated January 4, 2022	<u>issued by Labcorp</u>	

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

# <u>LABORATORY CORPORATION OF AMERICA HOLDINGS</u> Registrant

By: /s/ SANDRA VAN DER VAART

Sandra van der Vaart

Executive Vice President, Chief Legal Officer and Corporate Secretary

January 5, 2022



#### **FOR IMMEDIATE RELEASE**

**LabCorp Contacts:** 

Investors: Chas Cook — 336-436-5076

Investor@Labcorp.com

Media: Christopher Allman-Bradshaw – 336-436-8263

Media@Labcorp.com

## LABCORP IS SCHEDULED TO VIRTUALLY PARTICIPATE AT THE 40TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

**BURLINGTON, N.C., Jan. 4, 2022** — Labcorp (NYSE: LH), a leading global life sciences company, today announced that members of the executive management team will participate in a virtual fireside chat at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 11 at 4:30 p.m (ET).

A live webcast of the presentation will be available via the Company website at www.Labcorp.com and archived for replay.

#### **About Labcorp**

Labcorp is a leading global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. Through our unparalleled diagnostics and drug development capabilities, we provide insights and accelerate innovations to improve health and save lives. With more than 70,000 employees, we serve clients in more than 100 countries. Labcorp (NYSE: LH) reported revenue of \$14 billion in FY2020. Learn more about us at <a href="https://www.labcorp.com">www.labcorp.com</a> or follow us on <a href="https://www.labcorp.com">LinkedIn</a> and Twitter @Labcorp.